Table 1 |
|||
|
Subject characteristics (N = 100) |
|||
|
Characteristic |
Categories |
Number |
Percent (%) |
|
|
|||
|
Ethnicity |
Caucasian |
81 |
81 |
|
African American |
15 |
15 |
|
|
Hispanic |
3 |
3 |
|
|
Asian |
1 |
1 |
|
|
|
|||
|
Tumor Stage at Diagnosis |
Stage 0 |
4 |
4 |
|
Stage I |
21 |
21 |
|
|
Stage II |
44 |
44 |
|
|
Stage III |
17 |
17 |
|
|
Stage IV |
11 |
11 |
|
|
Unknown |
3 |
3 |
|
|
|
|||
|
Menstrual Status |
Premenopausal |
53 |
53 |
|
Postmenopausal |
37 |
37 |
|
|
Perimenopausal |
4 |
4 |
|
|
Unknown |
6 |
6 |
|
|
|
|||
|
ER/PR status |
ER + PR + |
48 |
48 |
|
ER + PR - |
11 |
11 |
|
|
ER - PR + |
1 |
1 |
|
|
ER - PR - |
36 |
36 |
|
|
Unknown |
4 |
4 |
|
|
|
|||
|
Tamoxifen/Arimidex use |
Neither |
50 |
50 |
|
Tamoxifen only |
29 |
29 |
|
|
Arimidex only |
7 |
7 |
|
|
Both |
11 |
11 |
|
|
Unknown |
3 |
3 |
|
|
|
|||
|
Lammersfeld et al. Nutrition Journal 2009 8:2 doi:10.1186/1475-2891-8-2 |
|||
